Open AccessArticle by Erwin Setiawan 1,2, Chrismis Novalinda Ginting Chrismis Novalinda Ginting 1, Jonny Jonny 1,3,4,5, Bhimo Aji Hernowo 1,6 and Terawan Agus Putranto 1,4,6,7,* 1 Faculty of Medicine, Dentistry, and Health Science, Universitas Prima Indonesia, Medan 20118, Indonesia 2 Department of Neurology, Gatot Soebroto Central Army Hospital, Jakarta 10410, Indonesia 3 Faculty of Military Medicine, Indonesia Defence University, Bogor 16810, Indonesia 4 Faculty of Medicine, Universitas...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Terawan Agus Putranto
Clinical Trial of Autologous Dendritic Cell Administration Effect on Water Molecule Diffusion and Anti-Inflammatory Biomarkers in Diabetic Kidney Disease
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open-Label Clinical Trial on the Impact of Autologous Dendritic Cell Therapy on Albuminuria and Inflammatory Biomarkers (Interleukin-6, Interleukin-10, Tumor Necrosis Factor α) in Diabetic Kidney Disease (DKD)
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Potential of Anti-Inflammatory DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus
Preprint Review Version 1 This version is not peer-reviewed Version 1 : Received: 10 July 2024 / Approved: 10 July 2024 / Online: 10 July 2024 (12:42:53 CEST) Jonny, J.; Sitepu, E. C.; Lister, I. N. E.; Chiuman, L.; Putranto, T. A. The Potential of DC Immunotherapy in Improving Proteinuria in Type 2 Diabetes Mellitus. Preprints 2024, 2024070862. https://doi.org/10.20944/preprints202407.0862.v1 Jonny, J.; Sitepu, E. C.; Lister, I. N. E.; Chiuman, L.; Putranto, T. A.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Terawan Agus
Contact Terawan Agus, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack